Revitope Oncology

Revitope Oncology is revolutionizing immunotherapy to safely and effectively treat more cancers, bringing hope to patients for healthier and longer lives. Revitope is transforming the way immunotherapeutic drugs are designed. Revitope is led by a team of creative, highly engaged scientists and industry veterans who have deep experience in protein engineering and immunotherapy with a proven track record of delivering effective biologic therapies that treat cancer and other serious immunological diseases. Revitope’s platform is a suite of proprietary and modular bispecific antibodies designed to deliver improved therapeutic efficacy and safety through built-in control mechanisms that enable exquisite tumor-specificity. Revitope, the Revitope logo and TwoGATE™ are registered trademarks of Revitope Oncology Inc. Revitope’s PrecisionGATETM Technology Platform is designed to develop antibody-based bispecific immunotherapies that minimize toxicity to widen the therapeutic window and provide more efficacious cancer treatments. Revitope’s proprietary Precision Guided Antibody Tumor EngagerÔ (PrecisionGATE) technology platform exploits co-expressed tumor antigens to enable the development of highly specific cancer drugs with improved safety and efficacy over conventional immunotherapeutic approaches. Revitope will leverage its proprietary protein engineering platform together with Junshi’s novel antibody components to develop first-in-class dual-antigen targeting cancer therapies.